89980-92-7

Usage

Uses

Used in Pharmaceutical Industry:
1,4-Benzenedimethanol, 2-bromoserves as a key intermediate in the synthesis of various pharmaceuticals. Its unique structure allows for the development of new drugs with specific therapeutic properties, contributing to advancements in medicinal chemistry.
Used in Polymer Production:
In the polymer industry, 1,4-Benzenedimethanol, 2-bromoacts as a vital building block for the creation of diverse polymers. These polymers can be tailored for specific applications, such as in plastics, coatings, and adhesives, due to the compound's reactive functional groups.
Used in Resin Manufacturing:
1,4-Benzenedimethanol, 2-bromois also employed in the production of resins, where its chemical properties enable the formulation of resins with tailored characteristics for use in various industrial applications, including coatings, composites, and adhesives.
Overall, 1,4-Benzenedimethanol, 2-bromois a multifaceted chemical with applications across different industries, primarily due to its role as a synthetic building block and its solubility in various solvents.

Upstream product

• 18643-86-2 dimethyl 2-bromoterephthalate 
• 7697-26-9 3-bromo-4-methylbenzoic acid 
• 553-94-6 4-bromo-m-xylene 
• 13815-89-9 2-bromobenzene-1,4-dicarbonyl dichloride 
• 586-35-6 2-bromo-1,4-benzenedicarboxylic acid 
• 154239-21-1 diethyl 2-Bromoterephthalate 
• 90001-43-7 2-bromobenzene-1,4-dicarbaldehyde 

Downstream Products

• 56403-24-8 α,α'-dichloro(bromo)-p-xylene 
• 403699-41-2 2,2’-(2-bromo-1,4-phenylene)bis(methylene)bis(oxy)bis(tetrahydro-2H-pyran) 
• 1195621-94-3 1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborole-6-carbaldehyde 
• 1268390-58-4 (E)-[3-(1,3-dihydro-1-hydroxy-2,1-benzoxaborol-6-yl)-1-phenyl]propenone 
• 1365620-55-8 (E)-[3-(biphenyl-4-yl)-1-(1,3-dihydro-1-hydroxy-2,1-benzoxaborol-6-yl)]propenone 
• 1365620-95-6 3-(1,3-dihydro-1-hydroxy-2,1-benzoxaborol-6-yl)-1-phenyl-propanone 
• 1365620-96-7 (E)-1,3-dihydro-1-hydroxy-6-(3-hydroxy-3-phenylprop-1-enyl)-2,1-benzoxaborole 
• 1365620-61-6 (E)-[1-(1,3-dihydro-1-hydroxy-2,1-benzoxaborol-6-yl)-3-(4-nitrophenyl)]propenone 
• 1365620-62-7 (E)-[1-(1,3-dihydro-1-hydroxy-2,1-benzoxaborol-6-yl)-3-(4-(trifluoromethyl)phenyl)]propenone 
• 1365620-63-8 (E)-ethyl 4-(3-(1,3-dihydro-1-hydroxy-2,1-benzoxaborol-6-yl)acryloyl)benzoate 
• 1365620-64-9 (E)-4-(3-(1,3-dihydro-1-hydroxy-2,1-benzoxaborol-6-yl)acryloyl)benzoic acid 
• 1365620-65-0 (E)-[1-(1,3-dihydro-1-hydroxy-2,1-benzoxaborol-6-yl)-3-(4-fluorophenyl)]propenone 
• 1365620-66-1 (E)-[3-(4-chlorophenyl)-1-(1,3-dihydro-1-hydroxy-2,1-benzoxaborol-6-yl)]propenone 
• 1365620-67-2 (E)-[3-(4-bromophenyl)-1-(1,3-dihydro-1-hydroxy-2,1-benzoxaborol-6-yl)]propenone 

Relevant academic research and scientific papers

QUINAZOLINE DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS

The present disclosure provides certain quinazoline compounds that inhibit ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) enzymatic activity and are therefore useful for the treatment of diseases and conditions modulated at least in part by ENPP1. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

PROTECTIVE GROUPS AND METHODS FOR PROTECTING BENZOXABOROLES OR OXABOROLES

The present invention relates in part protective groups that can be used to reversibly protect benzoxaboroles and/or oxaboroles and yield the corresponding protected complexes. The invention further relates to the use of these protective groups to protect benzoxaboroles and/or oxaboroles.

BIS-BENZIMIDAZOLE COMPOUNDS AND METHODS OF USING SAME

Provided herein are compounds and methods for modulating abnormal repeat expansions of gene sequences. More particularly, provided are inhibitors of RNA and the uses of such inhibitors in regulating nucleotide repeat expansions, e.g., to treat Myotonic Dystrophy Type 1 (DM1 ), Myotonic Dystrophy Type 2 (DM2), Fuchs dystrophy, Huntington Disease, Amyotrophic Lateral Sclerosis, or Frontotemporal Dementia.

Design, synthesis and biological evaluation of 6-deoxy O-spiroketal C-arylglucosides as novel renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes

In this work, aiming at finding a novel, potent, and selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor with good pharmacokinetic profiles for the treatment of diabetes, we focus on modifying the sugar moiety of SGLT2 inhibitors, which dominates the binding with glucose binding site of hSGLT, via removing the C-6 hydroxy group to adjust the physicochemical properties and target-recognition manners of SGLT2 inhibitors. In addition, tofogliflozin containing a special O-spiroketal C-arylglucoside scaffold, displayed good efficacy and bioavailability both in animals and in humans. Therefore, a series of 6-deoxy O-spiroketal C-arylglucosides as novel SGLT2 inhibitors were designed, synthesized, and evaluated in this work. The structure-activity relationship (SAR) research on this novel series and a comprehensive in vitro and in vivo biological evaluation afforded compound 39 with high in vitro hSGLT2 inhibitory activity (IC50 = 4.5 nM), good pharmacokinetic profiles, and more remarkable efficacy in C57BL/6J mice and Sprague-Dawley rats than marketed drug tofogliflozin.

C,O-SPIRO ARYL GLYCOSIDE COMPOUNDS, PREPARATION THEREFOR AND USE THEREOF

The present invention provides C, O-spiro aryl glycoside compounds, preparation therefor and use thereof. Specifically provided are the compounds represented by the formula (I), wherein the definitions of each group are described in the specification. The

Protection of the Benzoxaborole Moiety: Synthesis and Functionalization of Zwitterionic Benzoxaborole Complexes

The synthesis and utility of three benzoxaborole protecting groups are reported. These protecting groups improve organic solubility and allow otherwise incompatible reactions (oxidations, substitutions, and mild reductions) to be achieved in the presence of the benzoxaborole moiety. 3-(N,N-Dimethylamino)-1-propanol was determined to be useful in one-step sequences and is readily cleaved upon workup. Two other groups, N-methylsalicylidenimine and 2-[1-(methylimino)ethyl]phenol, are suitable for multistep syntheses. Deprotection with mild aqueous acid allows for chromatography-free isolation of the benzoxaborole in high yields.

THERAPEUTIC INHIBITORY COMPOUNDS

Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for inhibiting plasma kallikrein. Furthermore, the subject compounds and compositions are useful for the treatment of diseases wherein the inhibition of plasma kallikrein inhibition has been implicated, such as angioedema and the like.

Chalcone–benzoxaborole hybrids as novel anticancer agents

In this study, we report the synthesis of a series of chalcone–benzoxaborole hybrid molecules and the evaluation of their anticancer activity. Their anticancer potency and toxicity were tested on three human cancer cell lines and two normal cell lines. The 4-fluoro compound 15 was found to be the most potent compound with an IC50value of 1.4 μM on SKOV3 cells. The 4-iodo compound 18 and 3-methyloxy-4-amino compound 47 showed good potency on SKOV3 cells while exhibiting low toxicity on normal cells. This work extended the application of benzoxaboroles to the field of anticancer research.

Method for preparing derivatives of spiroketal

Provided is a process for the preparation of a spiroketal derivative via a compound represented by general formula (II) [wherein each variable group and each variable number are as defined in the description].

Development of a Scalable Synthesis of Tofogliflozin

An efficient and scalable synthesis of an antidiabetic drug, tofogliflozin (1), which was identified as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor, is described. A key factor in the synthesis of 1 was the selection of the purpose-designed protecting group, which plays a strategic role in protection, chemoselective activation, and crystalline purification. The developed and optimized method made it possible to prepare 1 on a multidecagram scale without any column chromatography.